Company intelligence

HCWB

HCW Biologics Inc. · NASDAQ · Healthcare

Price$2.60+12.55% · +$0.29

Market cap903.87KEquity value

P / E-0.1Trailing ratio

Volume278.23KLatest session

Market data

HCWB price chart

TradingView

Related signals

1 min delayed

Browse public HCWB signals with their source context and measured market impact. Open any signal for its permanent analysis page.

HCWBJun 16, 2026-2.56% since signal

HCW Biologics' HCW9302 shows early efficacy with Phase 2 milestone looming

HCW Biologics reported positive early results for HCW9302 in alopecia areata, with all second-dose participants responding after a single dose and no serious adverse events. The company plans dose escalation and aims to define a Phase 2 dose by end-2026, supported by a favorable safety profile. The stock dipped on the news, implying potential upside on a future readout.

View signal analysis

HCWBAug 25, 2025-16.19% since signal

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

HCWB stock surged 58.79% amid high trading volume. The company developed second-generation pembrolizumab-based immunotherapeutics. These therapeutics target pancreatic and ovarian cancers more effectively. ICIs have a low response rate, affecting their efficacy. HCWB aims to enhance ICIs by neutralizing TGF-β.

View signal analysis

HCWBNov 18, 2024-9.47% since signal

Why Is Penny Stock HCW Biologics Surging On Monday?

HCW Biologics stock surged 237% in premarket trading. The company secured a $7 million upfront payment from WY Biotech. HCW Biologics can regain US rights after Phase 1 trial conclusion. Substantial doubt exists about the company's financial viability. They launched a financing plan to support product development.

View signal analysis

Research